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VDRAbstract Objective: To investigate the association between vitamin D receptor (VDR) gene FokI
polymorphism and atopic bronchial asthma in Egyptian children.
Material and methods: Polymerase chain reaction-restriction fragment length polymorphism was
used to determine VDR gene FokI polymorphism in 180 asthmatic children (atopic, n= 90 and
non-atopic, n= 90) and 180 age and gender matched healthy children. Serum levels of total IgE
were measured by ELISA. Skin prick test was performed on all patients.
Results: The frequency of FF genotype was signiﬁcantly higher in healthy children (n= 90,
50%) versus asthmatic children (n= 39, 21.7%, v2 = 5.852, OR = 0.23, 95% CI = 0.07–0.78,
p= 0.016). The frequency of FF genotype was signiﬁcantly higher among healthy children
(n = 90, 50%) compared to atopic asthmatic children (n= 12, 13.4%, v2 = 9.745, OR= 0.11,
95% CI = 0.02–0.46, p= 0.002). Also, its frequency was signiﬁcantly higher among non-atopic
asthmatic children (n= 27, 30%) compared to atopic asthmatic children (n= 12, 13.4%,
v2 = 4.394, OR= 0.21, 95% CI = 0.04–0.94, p= 0.041). Total IgE differed signiﬁcantly among
the three VDR gene FokI polymorphic genotypes in children with atopic asthma ( p= 0.007)
and the highest median level was detected in ff genotype.
Conclusion: Our ﬁndings raise the susceptibility of VDR gene to be a candidate gene for atopic
childhood bronchial asthma.
ª 2014 Production and hosting by Elsevier B.V. on behalf of The Egyptian Society of Chest Diseases and
Tuberculosis. Open access under CC BY-NC-ND license.Introduction
Vitamin D physiology has revealed that vitamin D is not
merely a micronutrient which plays a role in calcium
homeostasis but also a pluripotent hormone with immuno-
modulatory functions. It has also been found that the enzyme
1a-hydroxylase, which catalyzes the last and rate limiting step
548 E.S. Nabih, T.B. Kamelin the synthesis of active 1,25-dihydroxyvitamin D3, and the
vitamin D receptor (VDR), which mediates the actions of
vitamin D, are expressed widely in the body, including the
lungs and cells of immune system [1].
Emerging studies have supported the role of vitamin D in
asthma and allergy. In children with asthma, those with lower
serum vitamin D have a higher risk of hospitalization [2,3],
greater use of anti-inﬂammatory medications [2,4] and more
airway hyper-responsiveness [2,3]. Moreover, researchers
found that in children with asthma low serum vitamin D levels
were associated with higher IgE [2,5].
VDR, encoded by the VDR gene located within the region
q13–26 of chromosome 12, is a member of the nuclear receptor
family subgroup NR1I [6]. Multiple studies have reported a
signiﬁcant association between polymorphisms in VDR gene
and asthma as well as a range of autoimmune conditions,
although the ﬁndings between cohorts have not been uniform
[7–9]. However, no attempt was addressed to the question of
whether any of VDR gene variants could affect total IgE level.
Therefore, we selected a VDR gene FokI variant, which is
known to have a speciﬁed extent for asthma and/or other pul-
monary diseases [7,10], to evaluate its association with asthma
in Egyptian children. Moreover, its relation to total IgE and
the possibility of its role in atopic childhood asthma were
studied.Material and methods
This study included 180 asthmatic children (atopic, n= 90 and
non-atopic, n= 90) recruited from the Pediatric Chest Clinic,
Children’s Hospital, Ain Shams University. They were diag-
nosed according to the clinical manifestations [11] and con-
ﬁrmed by spirometry with measurements of FEV1 according
to the standards of the European Respiratory Society and
the American Thoracic Society [12]. Age and gender matched
non-atopic, non-asthmatic healthy children (n= 180) were
chosen as controls. They were selected from the geographic
area surrounding the place of study. There was no signiﬁcant
difference in school grade between children participating in
the study.
Skin prick tests (SPTs) were performed on all patients.
Atopy was deﬁned as at least one positive SPT result for com-
mon inhalant allergens (with positive histamine prick result). It
was carried out using stainless-steeled lancets. The panel used
was the Taiwan Asian panel (as it was found to be the most
matching panel to Egyptians)that includes; House dust Mite
Farinae, Mite pterony, Cockroach Mix, Feather Mix, Dogs’
and Cats’ dander, Candida, Aspergillus, Cladosporium ,Peni-
cillium, Alternaria, Grass Mix, Bremuda Grass,Wheat, Cod
ﬁsh, Pork, Beef, Egg, Whole, Egg Yolk, Milk, Yeast Brewer,
Soybean, Peanut, Vegetable Mix, Rag wd Mix II, Pine Mix,
Cotton wd, Mulberry Mi, Pigweed Mix, Corn, Crab, Shellﬁsh
Mix, Shrimp, and Eucalyptus [13,14]. Histamine solution
(10 mg/ml) and glycerinated saline were used as positive and
negative controls. SPTs were considered positive if there was
a wheal of 3 mm in diameter or larger.
This study has complied with the principles laid down in the
Declaration of Helsinki, adopted by the 18th World Medical
Assembly, Helsinki, Finland, June 1964, and recently amended
at the 64th World Medical Assembly, Fortaleza, Brazil, Octo-
ber 2013. The entire protocol was approved by institutionalethics committee. All parents or care givers provided signed in-
formed consent for participation in the study as required.
Blood sample collection and processing
Five milliliter of venous blood sample was withdrawn from
each participant under complete aseptic conditions and di-
vided into two portions as follows: 2.0 ml of blood was placed
in an EDTA containing tube for genotyping of VDR gene
FokI polymorphism and the remaining 3.0 ml of blood was
used for the separation of serum. The separated serum samples
were kept frozen at 80 C until used in the quantitative deter-
mination of total IgE according to the manufacturer’s instruc-
tions of the human total IgE ELISA kit (General Biologicals
Corporation, Taiwan).
Peripheral blood mononuclear cells (PBMCs) were sepa-
rated from blood samples according to the manufacturer’s
instructions of Sigma Histopaque-1077 (Sigma–Aldrich, Inc.,
St. Louis, MO, USA). DNA was extracted from PBMCs using
a QIAamp DNA blood mini kit (QIAGEN, Valencia, CA).
The DNA purity and concentration were determined by spec-
trophotometric measurement of absorbance at 260 and
280 nm. Following DNA extraction from isolated PBMCs, a
200 ll sample yielded 6 lg of DNA (30 ng/ll) with an A260/
A280 ratio of 1.7–1.9. Extracted DNA was stored at -80 C un-
til used.
Genotyping of VDR gene FokI polymorphism
The genotypes were determined by a standard Polymerase
Chain Reaction-restriction fragment length polymorphism
(PCR-RFLP) method.
Brieﬂy, PCR reaction was performed in 25 ll 1xPCR buffer
containing 20 pmol of each primer (Forward: 50-CCTGGCA
CTGACTCTGGCTCTG-30 and Reverse: 50-GGCTCCCTT
CATGGAAACACCT-30, GenBank: NT_029419.12), 2.5 mM
MgCl2, 200 mM of each dNTP, 50 ng DNA and 1.25 U Taq
polymerase. Following initial denaturation at 94 C for
5 min, ampliﬁcation was performed by 35 cycles of denatur-
ation at 94 C for 30 s, annealing at 57 C for 30 s and exten-
sion at 72 C for 30 s. Final extension was allowed to proceed
at 72 C for 5 min. 5 ll of each PCR product was digested
overnight with 1 U FokI restriction enzyme (MBI, Fermentas,
Lithuania) at 37 C. Electrophoresis was done through a 2%
agarose gel containing ethidium bromide then the gel was visu-
alized under UV illumination using gel documentation system
(BioRad-Gel. 2000, Italy). By using this protocol, a 270 bp
fragment encompassing the FokI polymorphic site was ampli-
ﬁed. FokI digested the ﬁrst ATG and yielded two products:
63 bp and 207 bp fragments (f allele), whereas the T to C tran-
sition destroyed the FokI site (F allele). Therefore, the homo-
zygous FF genotype displayed only 270 bp fragment, ff
homozygote displayed 63 bp and 207 bp fragments and Ff het-
erozygote displayed the three fragments.
Statistical analysis
The analysis was done using the Statistical Package for the So-
cial Sciences (SPSS software version 19, SPSS Inc., Chicago,
IL). Single nucleotide polymorphism (SNP) was assessed for
genotypic association analysis among asthmatic and healthy
Vitamin D receptor gene FokI polymorphism 549children. The genotype data of the tested SNP were then used
to estimate Hardy–Weinberg equilibrium by comparing geno-
type frequencies within groups by a v2-test. Fisher’s exact test
was applied to analyze the comparison of the frequencies of
discrete variables between asthmatic and healthy children.
The odds ratios (ORs) with 95% conﬁdence intervals (95%
CI) were also calculated to estimate risk of asthma associated
with the VDR gene FokI polymorphic genotypes. Using the
Non-Parametric Kruskal–Wallis (v2) test, the mean rank and
median of serum total IgE were estimated. Total IgE levelsTable 2 Genotype distribution of FokI VDR polymorphism betwe
Genotype Asthmatic children
(n= 180)
Healthy children
(n= 180)
FF 39 (21.7%) 90 (50%)
Ff 84 (46.7%) 60 (33.3%)
ﬀ 57 (31.6%) 30 (16.7%)
All groups were in Hardy–Weinberg equilibrium ( p> 0.5).
a ff genotype as reference (OR= 1.0).
* p< 0.05 is signiﬁcant.
Figure 1 Representative agarose gel electrophoresis for detection o
marker, lanes 1, 3 and 5: homozygous FF genotype; lanes 2, 4, 6, 8, 1
genotype.
Table 1 Clinical characteristics of asthmatic and healthy children.
Characteristics Asthmatic childre
Age (years ± SD) 7.98 ± 3.22
Total frequency of males (number, percent) 144 (80%)
Total frequency of females (number, percent) 36 (20%)
BMI (mean ± SD) 21.9 ± 4.0
FEV1 (% of predicted ± SD) 74.5 ± 12.5
Passive smoking (number, percent)
Positive 90 (50%)
Negative 90 (50%)
Family history of asthma (number, percent)
Positive 90 (50%)
Negative 90 (50%)
** p< 0.01 is highly signiﬁcant.were also correlated with VDR gene FokI polymorphic geno-
types. Statistical signiﬁcance was set at a value of p< 0.05.Results
The clinical characteristics of asthmatic and healthy children
are shown in Table 1. The products of PCR-RFLP are shown
in Figure 1. Genotype frequencies in asthmatic children
(p= 0.657) and healthy children (p= 0.171) were consistenten asthmatic and healthy children.
OR (95% CI) v2 P value
0.23 (0.07–0.78) 5.852 0.016*
0.74 (0.22–2.49) 0.241 0.431
1 (Ref.)a
f FokI VDR polymorphism. Lane (M): 100 bp molecular weight
0, 11: heterozygous Ff genotype and lanes 7 and 9 homozygous ff
n (n= 180) Healthy children (n= 180) P value
8.5 ± 2.22 0.411
144 (80%) 1.000
36 (20%) 1.000
17.6 ± 1.7 <0.001**
88.9 ± 8.2 <0.001**
54 (30%) 0.12
126 (70%)
0 (0%) <0.001**
180 (100%)
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550 E.S. Nabih, T.B. Kamelwith Hardy–Weinberg equilibrium. The frequency of FF geno-
type was signiﬁcantly higher in healthy children (n= 90, 50%)
versus asthmatic children (n= 39, 21.7%, v2 = 5.852,
OR= 0.23, 95% CI = 0.07–0.78, p= 0.016), Table 2. The
frequency of FF genotype was signiﬁcantly higher among
healthy children (n= 90, 50%) compared to atopic asthmatic
children (n= 12, 13.4%, v2 = 9.745, OR= 0.11, 95%
CI = 0.02–0.46, p= 0.002). Also, its frequency was signiﬁ-
cantly higher among non-atopic asthmatic children (n= 27,
30%) compared to atopic asthmatic children (n= 12,
13.4%, v2 = 4.394, OR= 0.21, 95% CI = 0.04–0.94,
p= 0.041), Table 3.
The mean rank and median of total IgE were signiﬁcantly
higher in atopic asthmatic children (p< 0.001) compared to
healthy and non-atopic asthmatic children, Table 4. Further-
more, total IgE differed signiﬁcantly among the three VDR
gene FokI polymorphic genotypes in children with atopic asth-
ma (p= 0.007) and the highest median level was detected in ff
genotype, (Table 5).
Discussion
This is the ﬁrst report that demonstrates a signiﬁcant associa-
tion between the FokI VDR gene polymorphism and the risk
of atopic childhood asthma in Egyptian children. It was specif-
ically noticed that children carrying FF genotype had a signif-
icantly lower prevalence of atopic asthma. These ﬁndings
represent another evidence for the role of vitamin D in child-
hood asthma.
Our ﬁndings are supported by several clinical and experi-
mental observations. Researchers found that vitamin D insuf-
ﬁciency is common in children with mild to moderate
persistent asthma and is associated with higher odds of severe
exacerbation [3]. Epidemiologic studies have shown that
maternal vitamin D intake during pregnancy protects from
childhood wheezing [15,16]. It has also been reported that chil-
dren whose mothers had high vitamin D levels in pregnancy
had an increased risk of eczema and asthma, suggesting that
the time point of vitamin D supplementation seems to deter-
mine the susceptibility to atopic disease [17]. Additionally, it
has been found that the FF genotype of VDR gene FokI poly-
morphism was associated with increased transcriptional activ-
ity of VDR [18–21]. On experimental level, in a murine asthma
model, the VDR was found to be necessary for the develop-
ment of an allergic airway inﬂammation [22].
Several studies classiﬁed VDR gene as one of the candidate
genes of asthma [7–8,23]. To our knowledge, no attempt was
addressed to the question of whether any of VDR gene vari-
ants could act as a protective or predictive variant for atopic
asthma. Since genotype frequencies of genes may vary accord-
ing to population and ethnicity, we conducted this study to
determine genotype frequencies of VDR gene FokI polymor-
phism in Egyptian asthmatic children. The relation between
this variant and the level of total IgE was evaluated. Also, po-
sitive skin prick test was done to conﬁrm the diagnosis of ato-
pic asthma.
In this study, the frequency of FF genotype was signiﬁ-
cantly higher among healthy children and non-atopic asth-
matic children compared to atopic asthmatic children. This
was in agreement with a recent study which detected signiﬁcant
difference in the distribution of FokI genotype frequencies be-
Table 4 Comparison between asthmatic and healthy children regarding serum total IgE.
Total IgE (IU/ll) Children with atopic
asthma (n= 90)
Children with non-atopic
asthma (n= 90)
Healthy children
(n= 180)
Statistics
Median (range) 344.5 (200–400) 99.5 (59–115) 64.5 (43–95) p< 0.001**
Mean Rank 75.5 39.68 21.32 v2 = 23.42
95% CI 251.7–365.8 84.3–105.8 55–83.5
** p< 0.01 is highly signiﬁcant.
Table 5 Relation between median levels of total IgE (IU/ll) and genotypes of FokI VDR polymorphism in different groups of the
study.
Groups Total IgE (IU/ll) Genotypes Statistics
FF Ff ﬀ
Children with atopic asthma Median (range) 218.5 (201–260) 250 (200–395) 360 (300–400) p= 0.007**
Mean Rank 6.0 13.31 20.62 v2 = 9.871
95% CI 205.5–255 222.6–340.5 344.8–391.9
Children with non-atopic asthma Median (range) 89 (59–112) 98 (60–115) 105.5 (99–112) p= 0.172
Mean Rank 12.78 14.83 21.25 v2 = 3.519
95% CI 60.4–109.3 66.3–107.5 99.6–111.6
Healthy children Median (range) 64 (49–93) 71.5 (43–95) 65 (47–85) p= 0.988
Mean Rank 15.70 15.45 15.0 v2 = 0.024
95% CI 51.3–85.4 44.5–92.6 48–84
** p< 0.01 is highly signiﬁcant.
Vitamin D receptor gene FokI polymorphism 551tween asthmatic and healthy children [24]. Indeed, another
study did not ﬁnd any relation between genotypes of FokI
VDR polymorphisms and asthma [25].
In an attempt to evaluate the association of VDR genetic
variants and susceptibility to atopy, researchers found that
TaqI, ApaI and BsmI VDR SNPs have been associated with
asthma and atopy [7]. In this study, it was not surprising that
median level of total IgE was signiﬁcantly higher in children
with atopic asthma compared to children with non-atopic
asthma and healthy controls. This result conﬁrmed the useful-
ness of total IgE as indicator of atopic diseases [26,27]. Fur-
thermore, we found that in children with atopic asthma the
homozygote ff genotype has been associated with the highest
median level of total IgE, while the homozygote FF genotype
has been associated with the lowest median level of total IgE.
The data we found do suggest that FF genotype could play a
protective role against atopic childhood asthma.
In conclusion, the elucidation of the precise role of VDR
polymorphism in the pathogenesis of atopic childhood asthma
has the potential to have profound effects on the ability to pre-
vent and treat this disorder. In this study, we have reported a
novel association between the FokI VDR gene polymorphism
and the risk of atopic childhood asthma. Further studies on a
large cohort of patients will be necessary to conﬁrm these ﬁnd-
ings. Along with other known asthma risk genes, the addition
of VDR involvement in the understanding of asthma/atopy
pathogenesis will shed light for better control and treatment.
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